On the other hand, when the meta-analysis of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) is evaulated it is observed that ER positivity is categorized and the benefit from ET is highest especially in the group with ER+>50% (18). This evidence concerns the gene ESR1 and breast carcinoma.